Keratoacanthoma - Queratoacantoma
☆ AI Dermatology — Free Service
En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
En els resultats de la Stiftung Warentest d'Alemanya de 2022, la satisfacció dels consumidors amb ModelDerm va ser només lleugerament inferior a la de les consultes de telemedicina de pagament.
Queratoacantoma típic (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) és un tumor cutani freqüent, conegut pel seu creixement ràpid i per la seva capacitat de regressar espontàniament. Normalment es presenta en homes d’edat avançada i de pell clara amb antecedents de dany solar. Tot i que l'extirpació quirúrgica, ja sigui per excisió o per cirurgia microgràfica de Mohs, és el tractament habitual, existeixen altres opcions terapèutiques disponibles.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) és un tumor de baix grau que s’inicia en determinades glàndules cutànies i sembla similar a squamous cell carcinoma (SCC) a l’observació microscòpica. Hi ha un debat en curs sobre si la KA s’ha de classificar com una forma invasiva de SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) és el segon tipus de càncer més comú en les persones, especialment en les persones grans. La cirurgia s'utilitza normalment per tractar el cSCC, però per a alguns pacients que no es poden operar o decideixen no fer‑ho, es poden considerar altres opcions com els tractaments intralesionals. S'han utilitzat tractaments intralesionals tradicionals (methotrexate or 5-fluorouracil), però hi ha investigacions en curs sobre nous enfocaments com la immunoteràpia intralesional i la viroteràpia oncolítica. A continuació, veurem diferents tractaments intralesionals per al cSCC, que van des dels mètodes clàssics fins a les estratègies d'avantguarda.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Al microscopi, el Queratoacantoma (Keratoacanthoma) s’assembla molt al carcinoma de cèl·lules escamoses. Tot i que alguns patòlegs el classifiquen com una entitat diferent i no com una malignitat, al voltant del 6 % dels casos clínics i histològics de Queratoacantoma (Keratoacanthoma) progressen cap a càncers de cèl·lules escamoses invasives i agressives.
○ Diagnòstic i tractament
#Dermoscopy
#Skin biopsy